Hercules Capital Dirección

Dirección controles de criterios 2/4

El CEO de Hercules Capital's es Scott Bluestein , nombrado en Apr 2014, tiene una permanencia de 4.75 años. compensación anual total es $8.89M, compuesta por 7.3% salario y 92.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.42% de las acciones de la empresa, por valor de $43.25M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 3.8 años, respectivamente.

Información clave

Scott Bluestein

Chief Executive Officer (CEO)

US$8.9m

Compensación total

Porcentaje del salario del CEO	7.3%
Permanencia del CEO	10.2yrs
Participación del CEO	1.4%
Permanencia media de la dirección	5.4yrs
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Hercules Capital: Solid 10% Yield, But Sky-High Valuation

May 10

Hercules Capital: VC-Focused Name With Less Risk And Better Return Prospects Than Average BDC

May 04

Unlocking Hercules Capital's Income Potential: A Fresh Look At Dividend Timing Strategies

Feb 23

Results: Hercules Capital, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Feb 18

Hercules Capital: Still Resilient With Solid Prospects Despite The VC Focus

Feb 17

Hercules Capital: A Different Type Of VC-Focused BDC

Jan 16

Hercules Capital Poised For Potential Market Surge In 2024

Dec 24

Lacklustre Performance Is Driving Hercules Capital, Inc.'s (NYSE:HTGC) Low P/E

Dec 18

10%-Yielding Hercules Capital: Better Ingredients, Better Outcomes

Dec 15

Main Street Capital Vs. Hercules Capital: Why Choose?

Nov 22

Hercules Capital: 10% Yield, My Largest BDC Position

Nov 13

10%-Yielding Hercules Capital Is A BDC Superstar

Oct 10

Hercules Capital: Venture Capital Financier Offering High Yield And Robust Balance Sheet

Sep 17

Hercules Capital: 10% Yield, Strong Coverage, Low Leverage

Sep 09

Let's Build A Bond Portfolio Together: Hercules Capital Bonds 2026 7.10%

Aug 15

Hercules Capital: Fatter Yield, Surging Stock Price

Aug 05

Hercules Capital: The Tide Is Turning - Buy While It's Cheap (Rating Upgrade)

Jun 28

Hercules Capital raises dividend by 8.3% to $0.39/share, supplemental cash distribution of $0.08

Feb 14

Hercules Capital: 2 Top Reasons To Buy This 10.1%-Yielding BDC

Jan 25

Should You Buy Hercules Capital Before Or After Its Ex-Dividend Date?

Jan 11

Hercules Capital: Bear Market Rally Fizzling Out

Dec 08

Oak Street Health secures $300M in financing

Nov 16

Hercules Capital: Double Your Cash Flow With This 10%+ Dividend

Nov 07

Hercules Capital raises dividend by 2.9% to $0.36, supplemental cash distribution of $0.15

Oct 18

Hercules Capital: Grab Its 13% Yield As Weak Holders Capitulate

Oct 03

Hercules Capital: 10% Yield, Wake Up And Smell The Cash Flow

Aug 31

Hercules Capital: 7% From An Investment Grade Bond With 4 Years To Maturity

Aug 23

atai Life Sciences nabs $175M in loan facility from Hercules Capital

Aug 15

Hercules Capital raises dividend by 6% to $0.35 , supplemental cash distribution of $0.15

Jul 26

Hercules Capital: 14% Yield, Benefits From Rising Rates, Good Upside Potential

Jul 03

Buy The Dip And Position For Higher Rates With Hercules Capital

Jun 02

Hercules Capital: Buy This Fat 9.7% Yield While It's On Sale

May 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Scott Bluestein en comparación con los beneficios de Hercules Capital?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$331m
Dec 31 2023	US$9m	US$650k	US$334m
Sep 30 2023	n/a	n/a	US$277m
Jun 30 2023	n/a	n/a	US$302m
Mar 31 2023	n/a	n/a	US$197m
Dec 31 2022	US$7m	US$650k	US$100m
Sep 30 2022	n/a	n/a	US$42m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$105m
Dec 31 2021	US$6m	US$650k	US$172m
Sep 30 2021	n/a	n/a	US$319m
Jun 30 2021	n/a	n/a	US$339m
Mar 31 2021	n/a	n/a	US$318m
Dec 31 2020	US$7m	US$650k	US$226m
Sep 30 2020	n/a	n/a	US$120m
Jun 30 2020	n/a	n/a	US$96m
Mar 31 2020	n/a	n/a	US$83m
Dec 31 2019	US$8m	US$594k	US$173m
Sep 30 2019	n/a	n/a	US$111m
Jun 30 2019	n/a	n/a	US$128m
Mar 31 2019	n/a	n/a	US$132m
Dec 31 2018	US$11m	US$515k	US$76m
Sep 30 2018	n/a	n/a	US$111m
Jun 30 2018	n/a	n/a	US$109m
Mar 31 2018	n/a	n/a	US$90m
Dec 31 2017	US$3m	US$500k	US$78m

Compensación vs. Mercado: La compensación total de Scott($USD8.89M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.59M).

Compensación vs. Ingresos: La compensación de Scott ha aumentado más de un 20% en el último año.

CEO

Scott Bluestein (46 yo)

10.2yrs

Permanencia

US$8,891,994

Compensación

Mr. Scott Bluestein serves as Chief Executive Officer, President and Director at Hercules Capital, Inc. since July 18, 2019. He is responsible for the Hercules lending policies and risk management practice...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Bluestein	CEO, Chief Investment Officer	10.2yrs	US$8.89m	1.43% $ 45.1m
Seth Meyer	CFO & Chief Accounting Officer	5.3yrs	US$3.04m	0.22% $ 6.9m
Christian Follmann	Chief Operating Officer	8.4yrs	US$1.21m	0.060% $ 1.9m
Kiersten Botelho	Corporate Secretary	2.4yrs	US$1.08m	0.031% $ 967.9k
Steve Kuo	Senior MD & Group Head of Technology	5.4yrs	sin datos	sin datos
Michael Hara	Managing Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Kate Kinlin	VP of Human Resources	no data	sin datos	sin datos
Roy Liu	Managing Director	20.2yrs	sin datos	sin datos
R. Jadot	Senior MD & Group Head of Life Sciences	5.1yrs	sin datos	sin datos
Michael Bowden	Managing Director of Portfolio Management	5.4yrs	sin datos	sin datos
Janice Bourque	Managing Director	14.2yrs	sin datos	sin datos
Lesya Kulchenko	Managing Director	5.4yrs	sin datos	sin datos

5.4yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HTGC es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Bluestein	CEO, Chief Investment Officer	4.9yrs	US$8.89m	1.43% $ 45.1m
Gayle Crowell	Independent Director	5.3yrs	US$215.00k	0.031% $ 963.5k
Robert Badavas	Chairman of the Board & Lead Independent Director	18.3yrs	US$310.00k	0.070% $ 2.2m
Pam Randhawa	Independent Director	2.6yrs	US$250.00k	0.0079% $ 248.4k
Nikos Theodosopoulos	Independent Director	less than a year	US$39.99k	0.00060% $ 18.9k
Thomas Fallon	Independent Director	9.9yrs	US$205.00k	0.057% $ 1.8m
Wade Loo	Independent Director	2.9yrs	US$215.00k	0.013% $ 400.6k
DeAnne Aguirre	Independent Board Directors	2yrs	US$145.00k	0.0050% $ 157.8k

3.9yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de HTGC se considera experimentada (3.8 años de antigüedad promedio).

Hercules Capital Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024

Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee

Independent Director recently bought US$98k worth of stock

Independent Director recently bought US$98k worth of stock

Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board

CEO, Chief Investment Officer notifies of intention to sell stock

Recent updates

Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC completed the acquisition of ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others.

Hercules Capital: Solid 10% Yield, But Sky-High Valuation

Hercules Capital: VC-Focused Name With Less Risk And Better Return Prospects Than Average BDC

First quarter 2024 earnings: EPS exceeds analyst expectations

Fourth quarter dividend of US$0.48 announced

Hercules Capital, Inc. Declares First Quarter Cash Dividend, Payable on May 14, 2024

Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024

Hercules Capital: Winning Option In The Financial Services Space

There Is A Reason Hercules Capital, Inc.'s (NYSE:HTGC) Price Is Undemanding

Hercules Capital, Inc. to Report Q1, 2024 Results on May 02, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Hercules Capital: Record Year In 2023, 10% Yield

Unlocking Hercules Capital's Income Potential: A Fresh Look At Dividend Timing Strategies

Upcoming dividend of US$0.48 per share

Results: Hercules Capital, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Hercules Capital: Still Resilient With Solid Prospects Despite The VC Focus

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024

Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million.

Hercules Capital, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Hercules Capital: A Different Type Of VC-Focused BDC

Hercules Capital Poised For Potential Market Surge In 2024

Lacklustre Performance Is Driving Hercules Capital, Inc.'s (NYSE:HTGC) Low P/E

10%-Yielding Hercules Capital: Better Ingredients, Better Outcomes

Main Street Capital Vs. Hercules Capital: Why Choose?

Hercules Capital: 10% Yield, My Largest BDC Position

Consensus EPS estimates fall by 14%, revenue upgraded

Upcoming dividend of US$0.48 per share at 12% yield

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hercules Capital, Inc. Declares Total Cash Distribution the Third Quarter 2023, Payable on November 22, 2023

Hercules Capital, Inc. to Report Q3, 2023 Results on Nov 02, 2023

10%-Yielding Hercules Capital Is A BDC Superstar

New major risk - Revenue and earnings growth

Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee

Hercules Capital: Venture Capital Financier Offering High Yield And Robust Balance Sheet

Hercules Capital: 10% Yield, Strong Coverage, Low Leverage

Let's Build A Bond Portfolio Together: Hercules Capital Bonds 2026 7.10%

Upcoming dividend of US$0.48 per share at 11% yield

Hercules Capital, Inc. has completed a Follow-on Equity Offering.

Hercules Capital: Fatter Yield, Surging Stock Price

New major risk - Revenue and earnings growth

Price target increased by 8.8% to US$16.25

Hercules Capital Declares Cash Distribution for the Second Quarter 2023, Payable August 25, 2023

Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Hercules Capital: The Tide Is Turning - Buy While It's Cheap (Rating Upgrade)

Consensus EPS estimates increase by 10%

Independent Director recently bought US$98k worth of stock

Independent Director recently bought US$98k worth of stock

Upcoming dividend of US$0.47 per share at 15% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 19%

Upcoming dividend of US$0.47 per share at 13% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Hercules Capital Increases Its Quarterly Cash Distribution for the Fourth Quarter of 2022, Payable on March 9, 2023

Hercules Capital raises dividend by 8.3% to $0.39/share, supplemental cash distribution of $0.08

Hercules Capital, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board

Hercules Capital: 2 Top Reasons To Buy This 10.1%-Yielding BDC

Should You Buy Hercules Capital Before Or After Its Ex-Dividend Date?

Hercules Capital: Bear Market Rally Fizzling Out

CEO, Chief Investment Officer notifies of intention to sell stock

Oak Street Health secures $300M in financing

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 14%

Hercules Capital: Double Your Cash Flow With This 10%+ Dividend

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of US$0.51 per share

Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion.